Osteoporosis could prove deadly in postmenopausal women
Osteoporosis, which is highly prevalent in postmenopausal women, has long been associated with an increased risk of fractures. A new study suggests it may also increase a woman’s… read more.
Osteoporosis, which is highly prevalent in postmenopausal women, has long been associated with an increased risk of fractures. A new study suggests it may also increase a woman’s… read more.
argenx SE announced the FDA approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized… read more.
Bristol Myers Squibb announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2… read more.
Researchers at the University of São Paulo (USP) in Brazil have discovered that two osteoporosis drugs (etidronate and tiludronate) may combat diseases caused by iron accumulation in the… read more.
Researchers at Pompeu Fabra University (UPF) have made a great leap towards predicting the risk of hip fracture among people with osteoporosis and evaluating the effectiveness of specific… read more.
HRT via skin is best treatment for low bone density in women whose periods have stopped due to anorexia or exercise, says study. Hormone replacement therapy applied via… read more.
Scientists at Pompeu Fabra University (UPF) have made a great leap forward in predicting the risk of hip fracture among women due to osteoporosis. They have discovered that it is… read more.
A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that Tik Tok videos about gout are commonly misleading, inconsistent, or inaccurate. Gout is a painful… read more.
Fresenius announced the launch of its denosumab biosimilars, Conexxence (denosumab) and Bomyntra (denosumab), in Europe. These biosimilars received approval from the European Commission in July 2025 for all… read more.
Sandoz announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved… read more.
Alvotech announced that the European Commission (EC) has approved AVT 03 as a biosimilar to Prolia and Xgeva (denosumab). AV T03 is approved in two presentations: as a… read more.
AbbVie announced positive topline results from the Phase IIIb/IV head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (Rinvoq) 15 mg, once daily, compared to adalimumab (Humira)… read more.